Cover Image
市場調查報告書

甲狀腺疾病治療的全球市場 (甲狀腺機能低下症及甲狀腺功能亢進症) - 產業分析、規模、構成比、成長率、趨勢及預測:2015-2023年

Thyroid Gland Disorders Treatment Market (By Disorders - Hypothyroidism and Hyperthyroidism) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

出版商 Transparency Market Research 商品編碼 345766
出版日期 內容資訊 英文 104 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
甲狀腺疾病治療的全球市場 (甲狀腺機能低下症及甲狀腺功能亢進症) - 產業分析、規模、構成比、成長率、趨勢及預測:2015-2023年 Thyroid Gland Disorders Treatment Market (By Disorders - Hypothyroidism and Hyperthyroidism) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023
出版日期: 2015年10月15日 內容資訊: 英文 104 Pages
簡介

甲狀腺是由甲狀腺細胞形成,從食物吸收碘轉換成三碘甲腺胺酸 (T3) 和甲狀腺素 (T4) 。這些荷爾蒙放出到血流中,發揮控制代謝的重要作用。甲狀腺疾病定義為甲狀腺荷爾蒙放出的異常,治療需要適當的藥物。

本報告以甲狀腺疾病治療為焦點,提供甲狀腺功能降低治療和甲狀腺功能亢進治療區分、2015-2023年期間交易規模變遷的各地區預測、產業結構、供需趨勢、推動&阻礙因素、機會、競爭環境等分析資訊和主要加入企業簡介彙整。

第1章 序

  • 概要
  • 報告相關的說明
  • 市場區隔
  • 調查方法
  • 前提

第2章 摘要整理

  • 甲狀腺疾病治療市場 - 市場簡述
  • 甲狀腺疾病治療的全球市場收益 - 各對象疾病:2014年 (單位:100萬美元)
  • 甲狀腺疾病治療的全球市場收益 - 各藥物分類:2014年 (單位:100萬美元)
  • 甲狀腺疾病治療的全球市場構成比 - 各地區 (% - 金額為基礎)

第3章 產業分析

  • 簡介
  • 流行病學 - 甲狀腺疾病
    • 疾病的背景
    • 風險因素和共生病症
    • 北美的年齡、男女特有病例
    • 歐洲的年齡、男女特有病例
    • 亞太地區的年齡、男女特有病例
    • 其他地區的年齡、男女特有病例
  • 市場動態
    • 市場推動要素
      • 甲狀腺疾病發生數量的增加
      • 在肥胖症、糖尿病、心血管症患者增加上預測的甲狀腺疾病風險的增加伴隨的對症藥物需求
      • 在開發中國家擴大的疾病認識程序
    • 阻礙市場要素
      • 在客戶間要求替代治療聲音高漲
      • 甲狀腺疾病的無症狀性導致大量未確診的人口
    • 市場機會
      • 新興國家的實際成果擴大帶來持續成長機會
  • 法律規範 - 甲狀腺疾病治療的全球市場
  • 現象的影響度分析 - 甲狀腺疾病治療的全球市場
  • 市場向心力分析 - 甲狀腺疾病治療的全球市場
  • 各企業市場佔有率 - 甲狀腺疾病治療的全球市場:2014年 (%)

第4章 市場區隔 - 各對象疾病

  • 簡介
  • 甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 甲狀腺機能低下症治療的全球市場收益 - 各藥物:2013-2023年 (單位:100萬美元)
    • Levothyroxine的全球市場收益:2013-2023年 (單位:100萬美元)
    • Liothyronine的全球市場收益:2013-2023年 (單位:100萬美元)
  • 甲狀腺功能亢進症治療的全球市場收益 - 各藥物:2013-2023年 (單位:100萬美元)
    • Imidazole的全球市場收益:2013-2023年 (單位:100萬美元)
    • Propacil的全球市場收益:2013-2023年 (單位:100萬美元)

第5章 市場區隔 - 各地區

  • 甲狀腺疾病治療的全球市場收益 - 各地區:2013-2023年 (單位:100萬美元)
  • 北美的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 歐洲的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 亞太地區的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 亞太地區的甲狀腺疾病治療的全球市場收益 - 各國:2013-2023年 (單位:100萬美元)
    • 中國
    • 其他亞太地區各國
  • 中南美的甲狀腺疾病治療的全球市場收益 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 中南美的甲狀腺疾病治療的全球市場收益 - 各國:2013-2023年 (單位:100萬美元)
    • 巴西
    • 其他中南美各國
  • 中東、非洲的甲狀腺疾病治療的全球市場 - 各對象疾病:2013-2023年 (單位:100萬美元)
  • 其他地區的甲狀腺疾病治療的全球市場:2013-2023年 (單位:100萬美元)

第6章 建議

  • 研究開發活動的擴大
  • 對疾病的認識擴大及促銷宣傳活動的強化
  • 有效並用給藥的甲狀腺藥物治療

第7章 企業簡介

  • Abbott Laboratories
  • AbbVie, Inc.
  • Allergan plc
  • GlaxoSmithKline plc
  • Pfizer, Inc.
  • Lannett Company, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Novartis International AG
  • Sanofi
  • 武田藥品工業株式會社
目錄

Thyroid gland is made of thyroid cells that absorb iodine from food and convert it into triiodothyronine (T3) and thyroxine (T4). These hormones are released into the blood stream and play an important role in the regulation of metabolism. Thyroid gland disorders are defined as an abnormal release of thyroid hormones which may demand proper therapeutic agents to correct the disorder condition. This report studies the market in a view of different types of thyroid drugs i.e. hypothyroid drugs and hyperthyroid drugs. The report comprises an elaborate executive summary, which includes a market snapshot that provides market dynamics of various segments and sub-segments that are included in the report in a precise manner. Moreover, executive summary comprises waterfall diagram, which reflects the market size of various segments in the descending order.

A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global thyroid gland disorders treatment market and future opportunities has been provided in the market overview section. This section of the report also provides with market attractiveness analysis, epidemiology study, event impact analysis, regulatory framework and market share analysis by key players (%) operating in the thyroid gland disorders treatment market.

Based on disorders, the global thyroid gland disorders treatment market has been segmented into hypothyroidism and hyperthyroidism. The market for these types has been extensively analyzed for different thyroid gland disorders drugs based on sales revenue of the various generic and branded products developed by the manufacturers. The market size and forecast in terms of USD million for each disorder has been provided for the period from 2013 to 2023. The report on the thyroid gland disorders treatment market also provides with compounded annual growth rate (CAGR %) for each of the market segments mentioned above with the forecast period from 2015 to 2023, considering 2014 as the base year.

Geographically, the thyroid gland disorders treatment market has been categorized into North America, Europe, Asia-Pacific, Latin America, the Middle East and North Africa (MENA) and Rest of the World (RoW) which are further divided based on the disorder types i.e. hypothyroidism and hyperthyroidism. Asia Pacific, further comprises detailed country analysis for China and Rest of APAC. Likewise, Latin America extensively provides with the detailed countrywise analysis for Brazil and Rest of LATAM. The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2013 to 2023 along with CAGR (%) for the forecast period from 2015 to 2023. The research study also incorporates the competitive scenario of major players in these regions.

A list of recommendations has been provided for new entrants to help establish a strong presence and for existing market players to increase their market shares. The report concludes with the profiles of the major players in the thyroid gland disorders treatment market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include Abbott Laboratories, Lannett Company, Inc., Pfizer, Inc., Merck KGaA, and Mylan N.V.

The global thyroid gland disorders treatment market is segmented as follows

Global Thyroid Gland Disorders Treatment Market, by Disorders

  • Hypothyroidism
    • Levothyroxine
    • Liothyronine
  • Hyperthyroidism
    • Imidazole
    • Propacil

Global Thyroid Gland Disorders Treatment Market, by Geography

  • North America
    • Hypothyroidism
    • Hyperthyroidism
  • Europe
    • Hypothyroidism
    • Hyperthyroidism
  • Asia Pacific
    • Asia Pacific (APAC), by Disorders
      • Hypothyroidism
      • Hyperthyroidism
    • Asia Pacific (APAC), by Country
      • China
        • Hypothyroidism
          • Levothyroxine
          • Liothyronine
        • Hyperthyroidism
          • Imidazole
          • Propacil
      • Rest of APAC
        • Hypothyroidism
          • Levothyroxine
          • Liothyronine
        • Hyperthyroidism
          • Imidazole
          • Propacil
  • Latin America (LATAM)
    • Latin America, by Disorders
      • Hypothyroidism
      • Hyperthyroidism
    • Latin America, by Country
      • Brazil
        • Hypothyroidism
          • Levothyroxine
          • Liothyronine
        • Hyperthyroidism
          • Imidazole
          • Propacil
      • Rest of LATAM
        • Hypothyroidism
          • Levothyroxine
          • Liothyronine
        • Hyperthyroidism
          • Imidazole
          • Propacil
  • Middle East and North Africa (MENA)
    • Hypothyroidism
    • Hyperthyroidism
  • Rest of the World (RoW)
    • Hypothyroidism
    • Hyperthyroidism

Table of Contents

Chapter 1 Preface

  • 1.1 Overview
  • 1.2 Report Description
  • 1.2 Market Segmentation
  • 1.3 Research Methodology
  • 1.4 Assumptions

Chapter 2 Executive Summary

  • 2.1 Thyroid Gland Disorders Treatment Market: Market Snapshot
  • 2.2 Global Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2014 (US$ Mn)
  • 2.3 Global Thyroid Gland Disorders Treatment Market Revenue, by Drug Class, 2014 (US$ Mn)
  • 2.4 Global Thyroid Gland Disorders Treatment Market Share, by Geography (Value %) Year is missing here

Chapter 3 Industry Analysis

  • 3.1 Introduction
  • 3.2 Epidemiology: Thyroid Gland Disorders
    • 3.2.1 Disease Background
    • 3.2.2 Risk Factors and Comorbidities
    • 3.2.3 North America Age and Gender Specific Prevalent Cases
    • 3.2.3 Europe Age and Gender Specific Prevalent Cases
    • 3.2.3 Asia Pacific and Latin America Age and Gender Specific Prevalent Cases
    • 3.2.3 Rest of the World Age and Gender Specific Prevalent Cases
  • 3.3 Market Dynamics
    • 3.3.1 Market Drivers
    • 3.3.1.1 Increasing incidence of thyroid gland disorders expected to propel the market
    • 3.3.1.2 Rise in obese, diabetic, and cardiovascular patients is expected to increase the risk for thyroid disorders, thereby driving demand for thyroid drugs
    • 3.3.1.3 Growing disease awareness programs in developing regions
    • 3.3.2 Market Restraints
    • 3.3.2.1 Rising customer preference for alternative treatments
    • 3.3.2.2 Asymptomatic nature of thyroid disorders lead to large undiagnosed population
    • 3.3.3 Market Opportunities
    • 3.3.3.1 Expand footprint in emerging nations that offer sustained growth opportunities
  • 3.4 Regulatory Framework: Global Thyroid Gland Disorders Treatment Market
  • 3.5 Event Impact Analysis: Global Thyroid Gland Disorders Treatment Market
  • 3.6 Market Attractiveness Analysis: Global Thyroid Gland Disorders Treatment Market
  • 3.7 Company Market Share - Global Thyroid Gland Disorders Treatment Market (2014) (%)

Chapter 4 Market Segmentation, by Disorders

  • 4.1 Introduction
  • 4.2 Global Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
  • 4.3 Global Hypothyroidism Treatment Market Revenue, by Drug, 2013-2023 (US$ Mn)
    • 4.3.1 Global Levothyroxine Market Revenue, 2013-2023 (US$ Mn)
    • 4.3.2 Global Liothyronine Market Revenue, 2013-2023 (US$ Mn)
  • 4.4 Global Hyperthyroidism Market Revenue, by Drugs, 2013-2023 (US$ Mn)
    • 4.4.1 Global Imidazole Market Revenue, 2013-2023 (US$ Mn)
    • 4.4.2 Global Propacil Market Revenue, 2013-2023 (US$ Mn)

Chapter 5 Market Segmentation, by Geography

  • 5.1 Thyroid Gland Disorders Treatment Market Revenue, by Geography, 2013-2023 (US$ Mn)
  • 5.2 North America Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
  • 5.3 Europe Thyroid Gland Disorders Treatment Market, by Disorder, 2013-2023 (US$ Mn)
  • 5.4 Asia Pacific Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
  • 5.5 Asia Pacific Thyroid Gland Disorders Treatment Market Revenue, by Country, 2013-2023 (US$ Mn)
    • 5.5.1 China Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
    • 5.5.1.1 China Hypothyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 5.5.1.2 China Hyperthyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 5.5.2 Rest of APAC Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
    • 5.5.2.1 Rest of APAC Hypothyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 5.5.2.2 Rest of APAC Hyperthyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
  • 5.6 Latin America Thyroid Gland Disorders Treatment Market, by Disorder, 2013-2023 (US$ Mn)
  • 5.7 Latin America Thyroid Gland Disorders Treatment Market, by Country, 2013-2023 (US$ Mn)
    • 5.7.1 Brazil Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
    • 5.7.1.1 Brazil Hypothyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 5.7.1.2 Brazil Hyperthyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 5.7.2 Rest of LATAM Thyroid Gland Disorders Treatment Market Revenue, by Disorder, 2013-2023 (US$ Mn)
    • 5.7.2.1 Rest of LATAM Hypothyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
    • 5.7.2.2 Rest of LATAM Hyperthyroidism Market Revenue, by Drug Class, 2013-2023 (US$ Mn)
  • 5.8 MENA Thyroid Gland Disorders Treatment Market, by Disorder, 2013-2023 (US$ Mn)
  • 5.9 RoW Thyroid Gland Disorders Treatment Market, 2013-2023 (US$ Mn)

Chapter 6 Recommendations

  • 6.1 Increase in research and development activities
  • 6.2 Emphasis on spreading awareness about the disorders as well as promotional campaigns
  • 6.3 Development of effective combination thyroid drug therapy

Chapter 7 Company Profiles

  • 7.1 Abbott Laboratories
  • 7.2 AbbVie, Inc.
  • 7.3 Allergan plc
  • 7.4 GlaxoSmithKline plc
  • 7.5 Pfizer, Inc.
  • 7.6 Lannett Company, Inc.
  • 7.7 Merck KGaA
  • 7.8 Mylan N.V.
  • 7.9 Novartis International AG
  • 7.10 Sanofi
  • 7.11 Takeda Pharmaceutical Company Ltd.
Back to Top